4//SEC Filing
RESPONSE BIOMEDICAL CORP 4
Accession 0001437749-16-042842
CIK 0000806888operating
Filed
Nov 30, 7:00 PM ET
Accepted
Dec 1, 9:11 PM ET
Size
16.1 KB
Accession
0001437749-16-042842
Insider Transaction Report
Form 4
KEEGAN JOSEPH D
Director
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2016-11-29−20,000→ 0 totalExercise: $2.20Exp: 2022-04-02→ Common Stock (20,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2016-11-29−20,000→ 0 totalExercise: $3.10Exp: 2023-03-14→ Common Stock (20,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2016-11-29−5,000→ 0 totalExercise: $1.43Exp: 2024-03-19→ Common Stock (5,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2016-11-29−5,000→ 0 totalExercise: $0.85Exp: 2026-03-23→ Common Stock (5,000 underlying) - Disposition to Issuer
Common Stock
2016-11-29−73,850→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2016-11-29−5,000→ 0 totalExercise: $0.92Exp: 2025-03-19→ Common Stock (5,000 underlying)
Footnotes (7)
- [F1]Disposed of pursuant to the Agreement and Plan of Arrangement by and between the issuer and 1077801 B.C. Ltd., dated June 16, 2016 (the "Arrangement"), pursuant to which 1077801 B.C. Ltd. acquired all of the outstanding common shares of the issuer (other than those rolled over into the purchaser) in exchange for cash consideration of $1.12 CDN per share.
- [F2]Prices shown are denominated in Canadian dollars.
- [F3]100% of the options vest fully on the date which is one year after the date of grant.
- [F4]Pursuant to the terms of the Arrangement, out of money stock options were cancelled.
- [F5]100% of the options vest on March 20, 2016, subject to the reporting person's continued service as a director of the Company through each vesting date.
- [F6]In connection with the Arrangement, all outstanding options to purchase common shares of the issuer as of immediately prior to the effective time of the Arrangement, were deemed unconditionally vested and exercisable, and subsequently cancelled in exchange for cash payment equal to the difference between the per share consideration of $1.12 CDN and the per share exercise price of such option multiplied by the number of common shares issuable pursuant to such option, less applicable withholdings.
- [F7]Subject to the reporting person's continued service as a director of the company through each vesting date, 100% of the shares subject to the option shall vest and become exercisable on March 24, 2017.
Documents
Issuer
RESPONSE BIOMEDICAL CORP
CIK 0000806888
Entity typeoperating
IncorporatedBritish Columbia, Canada
Related Parties
1- filerCIK 0000806888
Filing Metadata
- Form type
- 4
- Filed
- Nov 30, 7:00 PM ET
- Accepted
- Dec 1, 9:11 PM ET
- Size
- 16.1 KB